Disclosure Of Effect Of Changes In Foreign Exchange Rates [Text Block]

Ascelia Pharma - Filing #689421

Concept	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2021-01-01 to 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31
Disclosure of effect of changes in foreign exchange rates [text block]	—	—	—		—	—	—	—	—	—	—	—	—	—	—	—
Reserve of exchange differences on translation	718,000 SEK	—	—	—	—	—	—	—	—	254,000 SEK	—	—	—	—	—	—
Disclosure of information when currency is not exchangeable into another currency [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of information when foreign operation’s functional currency is not exchangeable into presentation currency [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of summarised financial information about foreign operation [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of summarised financial information about foreign operation [abstract]
Disclosure of summarised financial information about foreign operation [line items]
Non-current assets	57 700 SEK	—	—	—	—	—	—	—	—	58 882 SEK	—	—	—	—	—	—
Current assets	160 869 SEK	—	—	—	—	—	—	—	—	274 611 SEK	—	—	—	—	—	—
Non-current liabilities	193,000 SEK	—	—	—	—	—	—	—	—	553,000 SEK	—	—	—	—	—	—
Current liabilities	37 518 SEK	—	—	—	—	—	—	—	—	25 106 SEK	—	—	—	—	—	—
Revenue	—	—	—	– SEK	—	—	—	—	—	—	—	—	—	—	– SEK	—
Profit (loss)	—	– SEK	131 223 SEK	131 223 SEK	131 223 SEK	– SEK	– SEK	– SEK	– SEK	—	– SEK	– SEK	125 903 SEK	– SEK	125 903 SEK	125 903 SEK
Other comprehensive income	—	—	—	718,000 SEK	—	—	—	—	—	—	—	—	—	—	135,000 SEK	—
Comprehensive income	—	– SEK	130 504 SEK	130 504 SEK	131 223 SEK	– SEK	718,000 SEK	– SEK	– SEK	—	– SEK	135,000 SEK	125 768 SEK	– SEK	125 768 SEK	125 903 SEK